Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Soleno Therapeutics (SLNO) Liabilities and Shareholders Equity: 2013-2019

Historic Liabilities and Shareholders Equity for Soleno Therapeutics (SLNO) over the last 5 years, with Sep 2019 value amounting to $28.7 million.

  • Soleno Therapeutics' Liabilities and Shareholders Equity fell 6.84% to $28.7 million in Q3 2019 from the same period last year, while for Sep 2019 it was $144.9 million, marking a year-over-year increase of 3.83%. This contributed to the annual value of $43.2 million for FY2018, which is 10.58% up from last year.
  • As of Q3 2019, Soleno Therapeutics' Liabilities and Shareholders Equity stood at $28.7 million, which was down 15.85% from $34.1 million recorded in Q2 2019.
  • Soleno Therapeutics' Liabilities and Shareholders Equity's 5-year high stood at $43.2 million during Q4 2018, with a 5-year trough of $5.5 million in Q2 2016.
  • In the last 3 years, Soleno Therapeutics' Liabilities and Shareholders Equity had a median value of $33.9 million in 2017 and averaged $34.1 million.
  • As far as peak fluctuations go, Soleno Therapeutics' Liabilities and Shareholders Equity tumbled by 36.89% in 2016, and later surged by 601.22% in 2017.
  • Over the past 5 years, Soleno Therapeutics' Liabilities and Shareholders Equity (Quarterly) stood at $8.2 million in 2015, then tumbled by 32.15% to $5.6 million in 2016, then soared by 601.22% to $39.0 million in 2017, then increased by 10.58% to $43.2 million in 2018, then declined by 6.84% to $28.7 million in 2019.
  • Its Liabilities and Shareholders Equity was $28.7 million in Q3 2019, compared to $34.1 million in Q2 2019 and $38.9 million in Q1 2019.